A patient at France’s National Eye Hospital of the Quinze-Vingts has been granted temporary authorization for use of Lumevoq, GenSight Biologics’ gene therapy for the treatment of Leber hereditary optic neuropathy, according to a press release.
Lumevoq, also known as GS010, targets LHON by leveraging a mitochondrial targeting sequence proprietary technology platform, which addresses defects in the mitochondria using an adeno-associated virus vector.
The French Competent Authority’s temporary authorization program allows a product not yet approved with a marketing authorization
Uncategorized